Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Bids Farewell To Blue Pill With New Double Helix Logo

'Reveals DNA At Heart' Of Science-Focused Firm

Executive Summary

CEO Albert Bourla says the rebranding "marks the advent of the new Pfizer – the culmination of a bold, decade-long transformation from a scientific fast follower to a first-in-class scientific powerhouse."

You may also be interested in...



Quick Listen: Scrip’s Five Must-Know Things

Join us for an audio catch-up on the latest major developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things. 

RedHill Could Soon Seek EUA For COVID-19 Therapy

The Israel-based, NASDAQ-listed biotech tells Scrip that if the oral SK2 selective inhibitor succeeds in a Phase II/III study, it would be "very comfortable" taking opaganib all the way to market on its own.

Investors Animated Over Aclaris Oral Rheumatoid Arthritis Therapy

Great progress has been made in the treatment of RA with biologics and JAK inhibitors but there is a space for effective small-molecule therapies and Aclaris hopes to fill it with ATI-450.

Topics

Related Companies

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel